Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
KRYSTAL-1: Adagrasib as monotherapy or combined with cetuximab in patients with ...
Dr Jared Weiss - UNC School of Medicine, Chapel Hill, USA
KRYSTAL-1: Adagrasib as monotherapy or combined with cetuximab in patients with CRC harboring a KRASG12C mutation ( Dr Jared Weiss - UNC School of Medicine, Chapel Hill, USA )
20 Sep 2021
Giredestrant plus palbociclib vs anastrozole plus palbociclib for post-menopausa...
Dr Sara Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA
Giredestrant plus palbociclib vs anastrozole plus palbociclib for post-menopausal, HER2-negative, untreated early breast cancer ( Dr Sara Hurvitz - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )
20 Sep 2021
Novel therapies in multiple myeloma
Dr Joseph Mikhael - Translational Genomics Research Institute, Pheonix, USA
Novel therapies in multiple myeloma ( Dr Joseph Mikhael - Translational Genomics Research Institute, Pheonix, USA )
20 Sep 2021
Overall survival with abiraterone acetate plus prednisone in PEACE-1 trial
Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France
Overall survival with abiraterone acetate plus prednisone in PEACE-1 trial ( Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France )
19 Sep 2021
STAR: First-line sunitinib or pazopanib for locally advanced and/or metastatic r...
Prof Janet Brown - University of Sheffield, Sheffield, United Kingdom
STAR: First-line sunitinib or pazopanib for locally advanced and/or metastatic renal cancer ( Prof Janet Brown - University of Sheffield, Sheffield, United Kingdom )
19 Sep 2021
First-line CDK 4/6 inhibition shows OS benefit for metastatic breast cancer
Prof Gabriel Hortobagyi - The University of Texas MD Anderson Cancer Center, Hou...
First-line CDK 4/6 inhibition shows OS benefit for metastatic breast cancer ( Prof Gabriel Hortobagyi - The University of Texas MD Anderson Cancer Center, Houston, Texas )
19 Sep 2021
CARTITUDE-2: Ciltacabtagene autoleucel in patients with progressive multiple mye...
Prof Adam Cohen - University of Pennsylvania, Philadelphia, USA
CARTITUDE-2: Ciltacabtagene autoleucel in patients with progressive multiple myeloma ( Prof Adam Cohen - University of Pennsylvania, Philadelphia, USA )
19 Sep 2021
Phase II trial: Tamoxifen + taselisib or placebo in patients with hormone recept...
Dr Mafalda Oliveira - Vall d'Hebron University Hospital, Barcelona, Spain
Phase II trial: Tamoxifen + taselisib or placebo in patients with hormone receptor positive (HR+)/HER2- metastatic breast cancer ( Dr Mafalda Oliveira - Vall d'Hebron University Hospital, Barcelona, Spain )
18 Sep 2021
B-cell maturation antigen targeted CD3-engaging bispecific molecule for relapsed...
Prof Bhagirathbhai Dholaria - Vanderbilt University Medical Center, Nashville, U...
B-cell maturation antigen targeted CD3-engaging bispecific molecule for relapsed or refractory multiple myeloma ( Prof Bhagirathbhai Dholaria - Vanderbilt University Medical Center, Nashville, USA )
18 Sep 2021
Cabozantinib in combination with atezolizumab in patients with mCRPC
Prof Neeraj Agarwal - University of Utah School of Medicine, Salt Lake CIty, US...
Cabozantinib in combination with atezolizumab in patients with mCRPC ( Prof Neeraj Agarwal -  University of Utah School of Medicine, Salt Lake CIty, USA )
18 Sep 2021
ESMO President: What to watch for at ESMO 2021
Prof Solange Peters - ESMO President
ESMO President: What to watch for at ESMO 2021 ( Prof Solange Peters - ESMO President )
17 Sep 2021
Clinical outcomes of relapsed/refractory multiple myeloma patients after BCMA-ta...
Dr Oliver Van Oekelen - Icahn School of Medicine at Mount Sinai, New York City, ...
Clinical outcomes of relapsed/refractory multiple myeloma patients after BCMA-targeted CAR T therapy ( Dr Oliver Van Oekelen - Icahn School of Medicine at Mount Sinai, New York City, USA )
10 Sep 2021